Amylyx Q1 net loss $41.3M; Phase 3 avexitide topline data in Q3 2026

Amylyx Pharmaceuticals, Inc.

2026-Q1 EPS reported -$0.37

Net loss of $41.3M ($0.37 per share) vs $35.9M ($0.42) in Q1 2025; cash used in operations.
Cash $279.8M at March 31, 2026, down from $317.0M; runway expected into 2028.
R&D expense rose to $27.6M, driven by avexitide trial costs and $4M Gubra milestone.
Phase 3 LUCIDITY for avexitide (PBH) enrollment complete; topline data in Q3 2026.
Early biomarker data from LUMINA Phase 1 for AMX0114 (ALS) expected at ENCALS June 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Amylyx Pharmaceuticals, Inc. reported first quarter ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026 was $41.3 million, or $0.37 per share, EPS $0.37 per share.

Period: first quarter ended March 31, 2026
Net income: Net loss for the three months ended March 31, 2026 was $41.3 million, or $0.37 per share
EPS: $0.37 per share
Result: reported results

Exact text from the filing

Net loss for the three months ended March 31, 2026 was $41.3 million, or $0.37 per share, compared to net loss of $35.9 million, or $0.42 per share, for the same period in 2025.

View on SEC.gov

Browse all earnings releases →

Amylyx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-210286

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.